rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 Drugs for Parkinson's Disease: Comprehensive Meta-Analysis of Efficacy and Safety

RPEP-097522025Abou Elezz, Amr M; Khalefa, Kareem; Gadelmawla, Ahmed Farid; Khattab, Youssef A; Abo Zeid, Mohamed
Meta AnalysisModerate evidence
The takeaway

Meta-analysis of antidiabetic drugs in Parkinson's disease found GLP-1 receptor agonists showed promising neuroprotective effects with improved motor and non-motor symptoms.

Motor + non-motor improvement

GLP-1 drugs improved both movement symptoms and cognitive/mood symptoms in Parkinson's disease meta-analysis

What the researchers found

GLP-1 receptor agonists showed promising efficacy for both motor and non-motor Parkinson's symptoms in a comprehensive meta-analysis of antidiabetic drugs in PD.

Why it matters

Parkinson's disease has no treatments that slow disease progression. If GLP-1 drugs are disease-modifying (not just symptomatic), they could transform PD care. This meta-analysis consolidates the evidence.

The numbers in context

Multiple RCTs were included. Both motor and non-motor symptoms were assessed as outcomes. GRADE evaluation provided formal certainty ratings.

How the study worked

Systematic review and meta-analysis of clinical trials testing antidiabetic drugs (including GLP-1 RAs) in Parkinson's disease patients. Assessed motor scores, non-motor outcomes, and safety.

Who was studied

Parkinson's disease patients across randomized controlled trials of antidiabetic medications

What this study cannot tell us

Meta-analysis heterogeneity due to different drugs, doses, and PD populations. Most individual trials were small. Long-term disease-modifying effects need confirmation in larger phase 3 trials.

How to read the evidence

Strong evidence: systematic meta-analysis of clinical trial data, though individual trials were relatively small and heterogeneous.

When this study was published

Published in 2025. Most comprehensive meta-analysis of metabolic drugs for Parkinson's to date.

The bigger picture

The exenatide Parkinson's trial showed persistent motor improvement after drug withdrawal — suggesting disease modification, not just symptom relief. This meta-analysis strengthens the case for GLP-1 drugs as potential disease-modifying treatments for neurodegeneration.

Questions still open

  • Which GLP-1 drug is most effective for Parkinson's neuroprotection?
  • Is the benefit disease-modifying or symptomatic?
  • Should PD patients with diabetes preferentially receive GLP-1 drugs over other diabetes treatments?

Common questions

Can diabetes drugs treat Parkinson's?
This meta-analysis shows GLP-1 drugs — a class of diabetes medications — improved both movement and non-movement symptoms of Parkinson's. While not yet approved for PD, clinical trials are ongoing and results are promising.
Do GLP-1 drugs slow Parkinson's progression?
Early evidence suggests they might. The exenatide trial showed motor improvements that persisted even after the drug was stopped, suggesting actual disease modification rather than just symptom relief. Larger trials are needed to confirm this.

Read the original research

Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.

Inflammopharmacology, 33(8), 4577-4593

View on PubMed ↗Publisher’s paper ↗

Citation

Abou Elezz, Amr M; Khalefa, Kareem; Gadelmawla, Ahmed Farid; Khattab, Youssef A; Abo Zeid, Mohamed. (2025). Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.. Inflammopharmacology, 33(8), 4577-4593. https://doi.org/10.1007/s10787-025-01873-0